Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-02-22
2010-12-28
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C424S093100
Reexamination Certificate
active
07858592
ABSTRACT:
The present invention relates to the inhibition of p53 transcription by interfering with the activity of a p53 promoter using inhibitory double-stranded RNAs. Use of these inhibitory RNAs in the treatment of cancers also is disclosed.
REFERENCES:
Brachman et al., Dominant-negative p53 mutations selected in yeast hit cancer hot spots, 1996, Proc. Natl. Acad. Sci., vol. 93, pp. 4091-4095.
Bergamaschi et al., p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis, 2003, Cancer Cell, vol. 3, pp. 387-402.
Bienz-Tadmor et al., “The 5′ region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element,”EMBO J., 4:3209-3213, 1985.
Bourdon et al., “p53 isoforms can regulate p53 transcriptional activity,”Genes Dev., 19:2122-2137, 2005.
Bumcrot et al., RNAi therapeutics: a potential new class of pharmaceutical drugs,Nature Chemical Biology, 2:711-719, 2006.
Garber, “Genetics. Small RNAs reveal an activating side,”Science, 314:741-2, 2006.
Janowski et al., “Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs,”Nature Chem. Biol., 1:216-222, 2005.
Janowski et al., “Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids,”Nature Chem. Biol., 1:210-215, 2005.
Janowski et al., “Involvement of AGO1 and AGO2 in mammalian transcriptional silencing,”Nat. Struct. Mol. Biol., 13:787-792, 2006.
Lamb and Crawford, “Characterization of the human p53 gene,”Molecular and Cellular Biology, 6:1379-1385, 1986.
Li et al., “Small dsRNAs induce transcriptional activation in human cells,”PNAS, 103:17337-17342, 2006.
Mills, “p53: link to the past, bridge to the future,”Genes and Development, 19:2091-2099, 2005.
Rohaly et al., “A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint,”Cell, 122:21-32, 2005.
Song et al., “RNA interference targeting Fas protects mice from fulminant hepatitis,”Nat. Med., 9:347-351, 2003.
Soutschek et al., “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs,”Nature, 432, 173-8, 2004.
Tang, “siRNA and miRNA: an insight into RISCs,”Trends Biochem. Sci., 30:106-114, 2005.
Toub et al., “Innovative nanotechnologies for the delivery of oligonucleotides and siRNA,”Biomedicine and Pharmacotherapy, 60:607-620, 2006.
Toyooka et al., “The TP53 gene, tobacco exposure, and lung cancer,”Hum. Mutat., 21:229-39, 2003.
Vogelstein et al., “Surfing the p53 network,”Nature, 408:307-10, 2000.
Zimmerman et al., RNAi-mediated gene silencing in non-human primates,Nature, 441:111-4, 2006.
Corey David R.
Greer Rachel S.
Minna John D.
Shames David S.
Bowman Amy
Fulbright & Jaworski
The Board of Regents of the University of Texas System
LandOfFree
Interfering RNAs against the promoter region of P53 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interfering RNAs against the promoter region of P53, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interfering RNAs against the promoter region of P53 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214175